A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type virus and Delta variant
L. Jiang, T. Driedonks, M. Lowman, W. S. Jong, H. B. van den Berg van Saparoea, S. Dhakal, R. Zhou, C. Caputo, K. Littlefield, I. Sitaras, M. W. Chen, G. Lima, O. Gololobova, B. Smith, V. Mahairaki, , K. W. Witwer
bioRxiv · Jun 28, 2021Immunology